FAQ

TZP-101

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2007-2015
012320072015

Related topics

Related topics

1 relation

Broader (1)

ulimorelin

Related mentions per year

Related mentions per year

2007-2015
20002005201020152020
TZP-101
ulimorelin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting--randomised clinical study subset data.
BACKGROUND Limited therapeutic options exist for severe gastroparesis, where severe nausea and vomiting can lead to weight loss… (More)
Is this relevant?
2011
2011
Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from hit to clinic.
High-throughput screening of Tranzyme Pharma's proprietary macrocycle library using the aequorin Ca2+-bioluminescence assay… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
2010
2010
Safety and efficacy of ghrelin agonist TZP-101 in relieving symptoms in patients with diabetic gastroparesis: a randomized, placebo-controlled study.
BACKGROUND Gastroparesis, a chronic disorder of abnormal gastric motility, is common in patients with diabetes mellitus. A… (More)
Is this relevant?
2010
2010
The Ghrelin agonist TZP-101 for management of postoperative ileus after partial colectomy: a randomized, dose-ranging, placebo-controlled clinical trial.
PURPOSE Ghrelin agonist TZP-101 is a potent prokinetic. This phase 2b study evaluated TZP-101 safety and efficacy in… (More)
Is this relevant?
2009
2009
Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis.
BACKGROUND TZP-101 is a synthetic, selective ghrelin agonist in development for gastroparesis. AIM To assess safety and effects… (More)
Is this relevant?
2009
2009
Effect of the ghrelin receptor agonist TZP-101 on colonic transit in a rat model of postoperative ileus.
Ghrelin, the natural ligand of the growth hormone secretagogue receptor (ghrelin receptor), is an orexigenic gut hormone with… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2009
2009
Contribution of protein binding to the pharmacokinetics of the ghrelin receptor agonist TZP-101 in healthy volunteers and adults with symptomatic gastroparesis: two randomized, double-blind studies…
BACKGROUND AND OBJECTIVE TZP-101 is a selective, small molecule ghrelin receptor agonist in clinical development for the… (More)
Is this relevant?
2008
2008
Ghrelin agonist (TZP-101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study.
The authors evaluate the human safety, tolerability, pharmacokinetics, and pharmacodynamics of TZP-101, an agonist of the hGHS… (More)
  • table I
  • table II
  • table III
  • figure 1
  • figure 2
Is this relevant?
2008
2008
Pharmacological demarcation of the growth hormone, gut motility and feeding effects of ghrelin using a novel ghrelin receptor agonist.
The peptide hormone ghrelin exerts a wide spectrum of activities including the stimulation of GH release, feeding, and… (More)
Is this relevant?
2007
2007
Prokinetic Effects of a New Ghrelin Receptor Agonist TZP-101 in a Rat Model of Postoperative Ileus
Postoperative ileus (POI) is a major cause of postoperative complications and prolonged hospitalization. Ghrelin, which is the… (More)
  • table 1
  • figure 2
  • figure 1
  • table 2
  • figure 3
Is this relevant?